top of page
TranspariMED logo

Guest blog: Sponsors should offer clinical trial participants their individual patient data

8 minutes ago
5 min read

In this guest blog, Rich Hutson argues that the companies and institutions running clinical trials should offer trial participants access to personal health data collected from them during a trial.

 

Every clinical trial participant gives a lot: their time, their samples and their data. Most of them never find out what happened next or what it meant for them.


A summary of clinical trial results on a public database alone does not answer the question participants actually ask: what did my trial find out about me?

 

Access to personal health data from trials


Individual patient data return (iPDR) is the missing jigsaw piece for comprehensive trial transparency.


It means giving each participant access to the data collected about them in a trial, should they wish to receive it, in a form they can understand and use, alongside the overall results.



That data can include which arm a patient was randomised to, lab results, imaging findings, responses given to questionnaires, and data from wearables - all contextualised in a report that can be shared directly with patients or via their clinical trial site.


Such reports can help to support aggregate reporting of overall trial results because an individual patient’s results can be combined with a plan language summary of the trial and shared in the same report.


Existing frameworks


The idea is not new, and appropriate frameworks already exist.


TransCelerate's iPDR toolkit, the MRCT Center's return of results work at Harvard, and more recently the IMI-funded FACILITATE project have all set out frameworks. Participants in the European Union can already request their data under GDPR Article 15, but few know they can, and few sponsors have the infrastructure in place to do this in a meaningful way.


The demand from patients and advocacy groups is also there. In CISCRP's 2023 Perceptions and Insights Study, 67% of the 11,000+ respondents wanted individual study results, and 89% said it matters that this information is in clear language they can share with their doctor.


Beyond one-way transparency


Most transparency effort points one way: releasing aggregate data from sponsors to regulators, researchers and the public.


That matters, and TranspariMED's work has shown what sustained awareness on reporting can achieve.


iPDR extends the same principle to the people who made the evidence possible. If results belong in the open rather than in a drawer, the participant, the first person with a stake in them, should not be the last to hear.


Real tangible benefits for patients


The benefits are practical to the patient and the wider healthcare system, as well as ethical.


Taking part in a clinical trial can provide the fullest picture of a person's health during their lifetime due to the increased frequency and number of assessments completed. That can then support better-informed conversations about care and, where it is scientifically and clinically feasible, can reduce repeated tests and procedures in future care.


A participant who holds their own lab results, imaging findings and clinical event data can pass them to their GP or specialist, who then has a fuller picture of what happened during the trial to make further treatment decisions.


Data from wearables and ePRO questionnaires gives patients a record of how their condition changed over time, which makes appointments more specific.


Participants who can see what their contribution produced are also better placed to decide whether to take part in research again, feeling that they were valued may make potential referral and enrolment in future studies more likely too.


Studies of lay summaries have also found that participants feel appreciated and more connected to the research once they receive one. Participants who feel their contribution counted are the ones sponsors will need next time, building trust in the system and improving recruitment and retention metrics over time - building out a real business case for sponsors to do this.


Meeting patients where they are


A results page on a company website treats returning results as a publishing task. It assumes the participant knows the page exists, remembers the study code, finds it years later, and can read a document written for a professional audience.


But: Many participants are unwell, older, or have limited digital access. The registry page is built for the sponsor's convenience, not theirs.


Meeting people where they are means starting from the participant's side:


  • Understanding which data is important to them and their condition, so that most relevant data can be surfaced.

  • A secure, personal link sent to them directly when results are available, rather than a public posting.

  • Plain language, in their own language, with a route to a person who can explain it.

  • Data in a portable format their own doctor can read, so it can inform their care.

  • Participant choice over what they receive, if anything, and clarity on what happens if they are unable to complete the trial for any reason.


Major challenges


Not every data point should be returned: some results are not clinically validated, and some could cause distress without additional explanation or counselling.


Blinded trials need careful timing to avoid introducing bias. Sites carry a huge workload and this could add extra burden even after a clinical trial has finished. Sponsors have a legal obligation to protect privacy and meet GxP expectations whilst making this additional information available - risking legal and reputational damage should sensitive data not be handled correctly.


The FACILITATE programme offers a sensible answer in proportionality: return what is validated and actionable as standard, and make exploratory data a participant choice. The common thread is planning and updating processes, as iPDR bolted on after database lock is doomed to fail.


How to release patient data


iPDR needs to be in the protocol, the consent form and the site materials from day one. Some sponsors are already doing this.


Pfizer, in a case study published by the MRCT Center, describes a programme that lets participants opt in to receive their trial data after the study ends. After market research with participants and clinicians, the team built a PDF report from its CDISC datasets.


The report covers treatment arm, adverse events, lab results, vital signs, ECG results and medical history, with graphics and links to plain language resources. Participants then access it on demand through Pfizer’s Clinical Trial Alumni Platform.


This is great news for participants on these specific trials, but the next step is to make this possible for all sponsors.


What transparency advocates can do


Campaigners already ask sponsors a simple question: where are your results?


They should add a second: were participants offered theirs? Ask whether the protocol and consent form say what will be returned, when and how. Funders and ethics committees can ask the same.


Transparency that stops at a registry entry is compliance. Transparency that reaches the participant is respect, and it builds the trust the whole system relies on.

 

This guest blog was written by Rich Hutson, an expert on digital health in clinical trials who has spent almost 15 years working in clinical research and has a keen interest in using technology to improve patient experience in research. He is working to build a platform to make it easy for sponsors to generate and share individual patient data reports and plain language summaries at EBB Clinical. Please reach out to Rich via LinkedIn if you are interested in collaborating or finding out more.

 

TranspariMED did not fact check any of the claims made in this blog. All opinions are those of the author alone.


New rules for sharing results with particpants


Note from TranspariMED:

  • In the UK, proactively offering to share the overall results of interventional clinical trials with participants is now a legal (for CTIMPs) and regulatory (for all trials, “where appropriate, unless otherwise justified”) requirement for sponsors.

  • In the United States, the National Institutes for Health recently published a draft policy that would require all NIH grantees to directly share the results of a broad range of health studies with participants.

  • In the European Union, sponsors have to post lay summary results onto the CTIS registry, but they do not have to send these lay results directly to participants.

     

At present, none of these rules require the kind of individual patient data return (iPDR) envisaged in the guest blog above..

 
 
 

Comments


Subscribe
Subscribe
Recent Posts
bottom of page